Indivior
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 647m | 791m | 901m | 1.1b | 1.2b | 1.2b | 1.4b |
% growth | (18 %) | 22 % | 14 % | 21 % | 8 % | 4 % | 10 % |
EBITDA | (121m) | 207m | (51.0m) | 62.0m | 340m | 381m | 464m |
% EBITDA margin | (19 %) | 26 % | (6 %) | 6 % | 29 % | 31 % | 34 % |
Profit | (148m) | 205m | (53.0m) | 2.0m | 116m | 260m | 373m |
% profit margin | (23 %) | 26 % | (6 %) | - | 10 % | 21 % | 27 % |
EV / revenue | 0.8x | 2.0x | 2.8x | 1.8x | 1.2x | 0.9x | 0.7x |
EV / EBITDA | -4.3x | 7.7x | -49.3x | 32.0x | 4.1x | 3.0x | 1.9x |
R&D budget | 40.0m | 52.0m | 72.0m | 106m | - | - | - |
R&D % of revenue | 6 % | 7 % | 8 % | 10 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
* | N/A | Post IPO Equity | |
Total Funding | - |
Related Content
Recent News about Indivior
EditIndivior is a global pharmaceutical company dedicated to developing medicines that treat substance use disorders and serious mental illnesses. The company operates in the healthcare sector, focusing on patients who suffer from addiction and mental health issues. Indivior's business model revolves around research and development of innovative treatments, which are then brought to market to improve patient outcomes. The company generates revenue through the sale of its pharmaceutical products, which are prescribed by healthcare professionals and used by patients worldwide. Indivior's commitment to patient safety and high-quality treatments is evident in its rigorous monitoring and reporting systems for product concerns and adverse events. By addressing critical healthcare needs, Indivior aims to create sustainable value and make a significant impact on global health.
Keywords: pharmaceutical, addiction treatment, mental health, substance use disorders, patient safety, innovative medicines, global healthcare, research and development, sustainable value, healthcare professionals.